About the project
A digital platform to connect breakthrough science with the capital behind it
CannBioRex Pharmaceuticals develops synthetic, pharmaceutical-grade cannabinoids for unmet medical needs, backed by research teams at the Kennedy Institute (Oxford University) and Hebrew University. Its science is advanced. Yet, its website was a static set of pages that could not carry the weight of that science.
The cost of that gap was real. Investors could not get a clear read on the pipeline, the market opportunity, or the financial story. Researchers and potential partners could not see the expertise or find a path to collaborate. And the science stayed locked behind technical language, so non-experts missed why any of it mattered. When a company this innovative cannot explain itself online, investor interest wanes, and collaboration opportunities slip away.
CannBioRex partnered with Lazarev.agency to build a real digital platform: a single, credible hub explaining what the company is building, who is behind it, and why it matters commercially, without watering down the science.










